"
HLB (028300.KS) Q1 2026: Net Loss Narrows 40%, FDA Ruling Looms
Quarterly loss shrinks to ₩40.9 billion on cost discipline, not drug revenues — the company's real inflection point rests entirely on the FDA's imminent ruling on rivoceranib.
Source: Quarterly Report (Q1 FY2026, 42nd Fiscal Year) — Filed July 19, 2026, with DART | Consolidated Financial Statements | Unit: ₩ billions
